Clinical Trials · NCT06987695
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- Amgen
- Enrollment
- 279
- Start date
- Jun 2025
- Locations
- 30 sites, Japan
- Primary endpoint
- Percent Change From Baseline in Body Weight at Week 72